The patient received Rabavert on days 0, 5, and 9 for post-exposure immunization.; Case reference number US-BN-2022-001179 is a spontaneous case report initially received on 02-Jun-2022 from a pharmacist (reference number USBAV22-0262) and concerns a *24-years old female patient*.  The patient's medical history and concomitant medication details were not provided.  *On 28-May-2022, after a dog bite happened the same day*, the patient was vaccinated with the first dose of RabAvert (Rabies Virus (Inactivated, Strain Flury LEP); batch number: unknown) at an unknown dose, route or site of administration for post-exposure immunization against rabies.  *On 02-Jun-2022, five days after the first dose, the patient was vaccinated with the second dose of Rabavert (batch number: YRBA831A) with a dose of 1 ml, intramuscular at right deltoid (explicitly coded as 'inappropriate schedule of vaccine administered').*  *On 06-Jun-2022, nine days after the first dose, the patient was vaccinated with the third dose of Rabavert (batch number: YRBA831A) with a dose of 1 ml, intramuscular at left deltoid (explicitly coded as 'inappropriate schedule of vaccine administered').*  At the time of this report, it was not known whether the patient experienced any adverse events.  Non-significant case correction received on 06-Jun-2022 from Bavarian Nordic included local case ID.  All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*).  Follow-up information received from the pharmacist on 21-Jun-2022 included: New information about the dates of vaccination, batch number, route, and site of administration, and new information which caused new event to be added.; Reporter's Comments: A 24-years old female patient was vaccinated with the first dose of RabAvert at an unknown dose, route or site of administration for post-exposure immunization against rabies. Five days after the first dose, patient received the second dose and nine days after the first dose patient received the third dose, which is considered as inappropriate schedule of vaccine administered. No associated adverse events have been reported with the reported medication error. Inappropriate schedule of vaccine administered is listed per company convention. The patient's medical history and concomitant medications details were not provided. Inappropriate schedule of vaccine administered is not related to the suspect vaccine, but to a human factor. This case is non-serious.; Sender's Comments: A 24-years old female patient was vaccinated with the first dose of RabAvert at an unknown dose, route or site of administration for post-exposure immunization against rabies. Five days after the first dose, patient received the second dose and nine days after the first dose patient received the third dose, which is considered as inappropriate schedule of vaccine administered. No associated adverse events have been reported with the reported medication error. Inappropriate schedule of vaccine administered is listed per company convention. The patient's medical history and concomitant medications details were not provided. Inappropriate schedule of vaccine administered is not related to the suspect vaccine, but to a human factor. This case is non-serious.